For LSD1, prioritize iadademstat + venetoclax ± HMA in unfit AML, with pharmacodynamic assays by week 2–3 to confirm enhancer rewiring and BCL-2 priming (Chatzilygeroudi et al., 2025). Here, KDM1A is linked to acute myeloid leukemia.